Gilead Taps Kymera in $750M Oncology Deal to Harness Molecular Glue Degraders
Gilead and Kymera seal a $750M deal for innovative CDK2 molecular glue degraders in oncology.
Topics
NICE Expands TAVI Guidance for Aortic Valve Regurgitation
Quick Summary: NICE has published new interventional procedures guidance recommending the use of transcatheter aortic valve implantation (TAVI) for patients with native aortic valve regurgitation. This guidance enables wider access to TAVI as a less invasive alternative to open-heart surgery for eligible NHS patients, with a key focus on multidisciplinary team-based patient selection and … Read more
NICE Guidance Catalyzes Digital Mental Health Innovation
NICE empowers NHS with digital health tech for children’s mental health, boosting access and efficiency.
Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
ENHERTU Advances First-Line Endometrial Therapy in Phase 3 Trial
ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
GoodRx Disrupts Pharmacy Economics with Cost-Plus Pricing
GoodRx reshapes independent pharmacy economics through transparent cost-plus pricing model launch.
Medacta Showcases Advanced Orthopedic Solutions at ISAKOS
Medacta highlights cutting-edge orthopedic innovations at ISAKOS 2024.
J&J Faces $442M Treble Damages Over Catheter Monopoly
J&J’s $147M antitrust penalty tripled to $442M for monopolizing cardiac catheter market.
UnitedHealth, Humana Back Medicare Home Visit Reforms
Major insurers endorse billing limits on controversial home-based risk assessments.
RedETSA Convenes 38 HTA Institutions for Americas Summit
Regional HTA network addresses equity, economic evaluation, and adaptation frameworks.